215 related articles for article (PubMed ID: 19062221)
1. Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Hsieh FY; Tengstrand E; Pekol TM; Guerciolini R; Miwa G
J Pharm Biomed Anal; 2009 Jan; 49(1):115-22. PubMed ID: 19062221
[TBL] [Abstract][Full Text] [Related]
2. [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
Cumová J; Jedličková L; Potěšil D; Sedo O; Stejskal K; Potáčová A; Zdráhal Z; Hájek R
Klin Onkol; 2012; 25(1):17-25. PubMed ID: 22348216
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
4. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
5. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Zangari M; Esseltine D; Cavallo F; Neuwirth R; Elice F; Burns MJ; Yaccoby S; Richardson P; Sonneveld P; Tricot G
Am J Hematol; 2007 Sep; 82(9):831-3. PubMed ID: 17546639
[TBL] [Abstract][Full Text] [Related]
7. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
[TBL] [Abstract][Full Text] [Related]
8. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
[TBL] [Abstract][Full Text] [Related]
9. Small protein biomarkers of culture in Bacillus spores detected using capillary liquid chromatography coupled with matrix assisted laser desorption/ionization mass spectrometry.
Wunschel D; Wahl J; Willse A; Valentine N; Wahl K
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Oct; 843(1):25-33. PubMed ID: 16798120
[TBL] [Abstract][Full Text] [Related]
10. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
[TBL] [Abstract][Full Text] [Related]
11. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
12. A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients.
Nanni P; Levander F; Roda G; Caponi A; James P; Roda A
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3127-36. PubMed ID: 19683480
[TBL] [Abstract][Full Text] [Related]
13. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses.
Mandal R; Sawyer MB; Li XF
Rapid Commun Mass Spectrom; 2006; 20(17):2533-8. PubMed ID: 16878345
[TBL] [Abstract][Full Text] [Related]
16. Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression.
Lo LH; Huang TL; Shiea J
Rapid Commun Mass Spectrom; 2009 Mar; 23(5):589-98. PubMed ID: 19165777
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC
Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography electrospray ionization and matrix-assisted laser desorption ionization tandem mass spectrometry for the analysis of lipid raft proteome of monocytes.
Zhang N; Shaw AR; Li N; Chen R; Mak A; Hu X; Young N; Wishart D; Li L
Anal Chim Acta; 2008 Oct; 627(1):82-90. PubMed ID: 18790130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
